LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Inicio・Lista de Acciones・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Abierto

SectorSanidad

24.09 -0.66

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

23.53

Máximo

24.42

Métricas clave
By Trading Economics
Ingresos	-85K 53M
Ventas	4.2M 153M
P/B Media del Sector	13.965 66.845
BPA	0.68
Margen de beneficios	34.53
Empleados	182
EBITDA	612K 81M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+41.86% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-28M 2.9B
Apertura anterior	24.75
Cierre anterior	24.09

Noticias sobre sentimiento de mercado

By Acuity

23%

77%

60 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

N/A / 24.28 Soporte y Resistencia

Catalyst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 mar 2026, 23:01 UTC

Ganancias

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises - Update

5 mar 2026, 21:54 UTC

Ganancias

Costco Posts Higher 2Q Profit on Rising Sales, Membership Fees

5 mar 2026, 21:35 UTC

Principales Movimientos del Mercado

ServiceNow Shares Rise After CEO Says AI Can Add Value to Software

6 mar 2026, 00:00 UTC

Noticias de Eventos Importantes

Its Missile Threat Degraded, Iran Is Taking Fewer Shots at More Targets -- WSJ

5 mar 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Decline Amid Concerns About Energy Costs -- Market Talk

5 mar 2026, 23:33 UTC

Charlas de Mercado

Gold Edges Higher on Possible Technical Recovery -- Market Talk

5 mar 2026, 23:27 UTC

Charlas de Mercado

Middle East Fighting Will Prompt RBA to Delay Hike -- Market Talk

5 mar 2026, 22:54 UTC

Charlas de Mercado

Ganancias

Costco Sold a $150,000 Diamond Ring in 2Q -- Market Talk

5 mar 2026, 22:50 UTC

Charlas de Mercado

Woodside Has More Exposure to Rising Gas Prices Than Santos -- Market Talk

5 mar 2026, 22:48 UTC

Ganancias

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

5 mar 2026, 22:46 UTC

Ganancias

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises -- Update

5 mar 2026, 22:44 UTC

Ganancias

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

5 mar 2026, 21:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

5 mar 2026, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

5 mar 2026, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

5 mar 2026, 21:35 UTC

Ganancias

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

5 mar 2026, 21:32 UTC

Ganancias

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

5 mar 2026, 21:26 UTC

Ganancias

These Stocks Are Today's Movers: Broadcom, Trade Desk, Berkshire Hathaway, Rigetti, Corning, Ciena, Expedia, and More -- Barrons.com

5 mar 2026, 21:24 UTC

Ganancias

Costco February Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 20.8% >COST

5 mar 2026, 21:23 UTC

Ganancias

Costco February Same-Store Sales Ex-Changes in Gas and Foreign Exchange Rose 7% >COST

5 mar 2026, 21:22 UTC

Ganancias

Costco 2Q Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

5 mar 2026, 21:21 UTC

Ganancias

Costco February Digitally-Enabled Sales Rose 21.8% >COST

5 mar 2026, 21:21 UTC

Ganancias

Costco Total Co Comparable Sales for February Rose 7.9% >COST

5 mar 2026, 21:20 UTC

Ganancias

Costco February Net Sales Were $21.69 B >COST

5 mar 2026, 21:20 UTC

Ganancias

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

5 mar 2026, 21:20 UTC

Ganancias

Costco Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

5 mar 2026, 21:19 UTC

Ganancias

Costco 2Q Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 21.7% >COST

5 mar 2026, 21:18 UTC

Ganancias

Costco 2Q Digitally-Enabled Sales Rose 22.6% >COST

5 mar 2026, 21:18 UTC

Ganancias

Costco 2Q Same-Store Sales Up 7.4% >COST

5 mar 2026, 21:15 UTC

Ganancias

Costco 2Q EPS $4.58 >COST

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

41.86% repunte

Estimación a 12 Meses

Media 34.5 USD 41.86%

Máximo 35 USD

Mínimo 33 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 24.28Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

60 / 351 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.